Abbott has announced that Health Canada has approved the Aveir single-chamber (VR) leadless pacemaker.
The Aveir leadless pacemaker is implanted directly inside the heart’s right ventricle via a minimally invasive procedure to treat slower-than-normal heart rates. Unlike traditional pacemakers, leadless pacemakers do not require an incision in the chest to implant the device or cardiac leads to deliver therapy, Abbott said in a press release.
The device has a unique mapping capability designed to allow physicians to measure electrical signals within the heart and determine the correct placement of the device before final implantation.
The news comes after the US Food and Drug Administration (FDA) approved Aveir VR in April 2022.